<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Classification of porphyrias (hepatic or erythropoietic; acute or cutaneous)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Classification of porphyrias (hepatic or erythropoietic; acute or cutaneous)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Classification of porphyrias (hepatic or erythropoietic; acute or cutaneous)</div><div class="cntnt"><table cellspacing="0"><colgroup span="5" width="7%"></colgroup><colgroup span="4" width="16%"></colgroup> <tbody> <tr> <td class="subtitle1" rowspan="2">Disease</td> <td class="subtitle1" colspan="2">Classification</td> <td class="subtitle1" rowspan="2">Enzyme affected</td> <td class="subtitle1" rowspan="2">Inheritance</td> <td class="subtitle1" colspan="4">Major biochemical findings*</td> </tr> <tr> <td class="subtitle2">Tissue site</td> <td class="subtitle2">Clinical features</td> <td class="subtitle2">Urine</td> <td class="subtitle2">Plasma</td> <td class="subtitle2">Erythrocytes</td> <td class="subtitle2">Feces</td> </tr> <tr> <td>ADP</td> <td>Hepatic<sup>¶</sup></td> <td>Acute</td> <td>ALAD</td> <td>Autosomal recessive</td> <td>ALA, coproporphyrin III</td> <td> </td> <td>Zinc protoporphyrin and low ALAD activity</td> <td> </td> </tr> <tr> <td>AIP</td> <td>Hepatic</td> <td>Acute</td> <td>PBGD</td> <td>Autosomal dominant</td> <td>ALA, PBG, uroporphyrin, coproporphyrin</td> <td> </td> <td>Low PBGD activity</td> <td> </td> </tr> <tr> <td>HCP</td> <td>Hepatic</td> <td>Acute and cutaneous</td> <td>CPOX</td> <td>Autosomal dominant</td> <td>ALA, PBG, uroporphyrin, coproporphyrin III</td> <td> </td> <td> </td> <td>Coproporphyrin III</td> </tr> <tr> <td>VP</td> <td>Hepatic</td> <td>Acute and cutaneous</td> <td>PPOX</td> <td>Autosomal dominant</td> <td>ALA, PBG, uroporphyrin, coproporphyrin III</td> <td>Fluorescence peak at approximately 626 nm</td> <td> </td> <td>Coproporphyrin III and protoporphyrin</td> </tr> <tr> <td>PCT</td> <td>Hepatic</td> <td>Cutaneous</td> <td>UROD</td> <td>Autosomal dominant<sup>Δ</sup></td> <td>Uroporphyrin and hepta-carboxyl-porphyrin</td> <td>Uroporphyrin and hepta-carboxyl-porphyrin</td> <td> </td> <td>Isocoproporphyrin</td> </tr> <tr> <td>HEP</td> <td>Hepatic<sup>¶</sup></td> <td>Cutaneous</td> <td>UROD</td> <td>Autosomal recessive</td> <td>Uroporphyrin and hepta-carboxyl-porphyrin</td> <td>Uroporphyrin and hepta-carboxyl-porphyrin</td> <td>Zinc protoporphyrin and low UROD activity</td> <td>Isocoproporphyrin</td> </tr> <tr> <td>CEP</td> <td>Erythropoietic</td> <td>Cutaneous</td> <td>UROS</td> <td>Autosomal recessive</td> <td>Uroporphyrin I and coproporphyrin I</td> <td>Uroporphyrin I and coproporphyrin I</td> <td>Uroporphyrin I and coproporphyrin I</td> <td>Coproporphyrin I</td> </tr> <tr> <td>EPP</td> <td>Erythropoietic</td> <td>Cutaneous</td> <td>FECH</td> <td>Autosomal recessive</td> <td> </td> <td>Protoporphyrin, fluorescence peak at approximately 634 nm</td> <td>Metal-free protoporphyrin</td> <td>Protoporphyrin</td> </tr> <tr> <td>XLP</td> <td>Erythropoietic</td> <td>Cutaneous</td> <td>ALAS2</td> <td>X-linked</td> <td> </td> <td>Protoporphyrin</td> <td>Metal-free and zinc protoporphyrin</td> <td>Protoporphyrin</td> </tr> </tbody></table></div><div class="graphic_lgnd">The table shows the classification based on tissue site (ie, hepatic or erythropoietic) and on clinical features (ie, acute or cutaneous). The affected enzymes, inheritance patterns, and biochemical findings are listed. Refer to UpToDate for details of initial testing for suspected porphyria and diagnostic evaluations for each specific porphyria.</div><div class="graphic_footnotes">ADP: delta-aminolevulinic acid (ALA) dehydratase porphyria; ALAD: ALA dehydratase; AIP: acute intermittent porphyria; PBGD: porphobilinogen (PBG) deaminase; HCP: hereditary coproporphyria; CPOX: coproporphyrinogen oxidase; VP: variegate porphyria; PPOX: protoporphyrinogen oxidase; PCT: porphyria cutanea tarda; UROD: uroporphyrinogen decarboxylase; HEP: hepatoerythropoietic porphyria; CEP: congenital erythropoietic porphyria; UROS: uroporphyrinogen III synthase; EPP: erythropoietic protoporphyria; FECH: ferrochelatase; XLP: X-linked protoporphyria; ALAS2: ALA synthase 2.<br/>* Increases of importance for diagnosis in most cases.<br/>¶ These hepatic porphyrias also have erythropoietic features, including increases in erythrocyte zinc protoporphyrin.<br/>Δ UROD inhibition in PCT is mostly acquired, but an inherited deficiency of the enzyme predisposes in familial (type 2) disease.</div><div class="graphic_reference">Karl Anderson, MD, FACP.</div><div id="graphicVersion">Graphic 80601 Version 11.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
